{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:26:39Z","timestamp":1793388399937,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.msard.2025.106550","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T01:31:53Z","timestamp":1748136713000},"page":"106550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosis"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0360-2993","authenticated-orcid":false,"given":"Jada","family":"Coker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106550_bib0017","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00415-023-12135-w","article-title":"Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing\u2013remitting multiple sclerosis: a 20-year follow-up cohort","volume":"271","author":"Arroyo Pereiro","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106550_bib0011","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102666","article-title":"Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients","volume":"47","author":"Bridel","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106550_bib0013","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1177\/13524585221097296","article-title":"Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis","volume":"28","author":"Brune","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106550_bib0021","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1177\/1352458520972573","article-title":"Temporal profile of serum neurofilament light in multiple sclerosis: implications for patient monitoring","volume":"27","author":"Calabresi","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106550_bib0039","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/acn3.51471","article-title":"Measuring treatment response to advance precision medicine for multiple sclerosis","volume":"8","author":"Calabresi","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0022","article-title":"Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: a post hoc analysis of the randomized CombiRx trial","volume":"9","author":"Cutter","year":"2023","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106550_bib0002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/NXI.0000000000000679","article-title":"Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS","volume":"7","author":"Engel","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106550_bib0008","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/eji.202149757","article-title":"Multiple sclerosis: immunopathological heterogeneity and its implications","volume":"52","author":"Engelhardt","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2025.106550_bib0028","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1212\/NXI.0000000000001003","article-title":"Serum neurofilament levels and pml risk in patients with multiple sclerosis treated with natalizumab","volume":"8","author":"Fissolo","year":"2021","journal-title":"Neurol. Neuroimmunol. NeuroInflammation"},{"key":"10.1016\/j.msard.2025.106550_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.msard.2025.106550_bib0019","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0023","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000856","article-title":"Long-term prognostic value of longitudinal measurements of blood neurofilament levels","volume":"7","author":"H\u00e4ring","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106550_bib0031","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/acn3.51524","article-title":"Development of an age-adjusted model for blood neurofilament light chain","volume":"9","author":"Harp","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104573","article-title":"Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study","volume":"91","author":"Hegen","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106550_bib0024","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/13524585241237388","article-title":"Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: a 48-week prospective single-center study","volume":"30","author":"Johnsson","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106550_bib0027","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/acn3.51568","article-title":"Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis","volume":"9","author":"Jons","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0003","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241239101","article-title":"Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis","volume":"17","author":"Kuhle","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106550_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106410","article-title":"The utility of serum neurofilament light chain in MOGAD: current insights and future directions","volume":"98","author":"Labib","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106550_bib0034","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16077","article-title":"Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients","volume":"31","author":"Midaglia","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0014","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2023.0010","article-title":"Association of serum neurofilament light chain levels at disease onset with disability worsening in patients with a first demyelinating multiple sclerosis event not treated with high-efficacy drugs","volume":"80","author":"Monreal","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2025.106550_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103280","article-title":"Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis","volume":"56","author":"Niiranen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106550_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012361","article-title":"Ella versus Simoa serum neurofilament assessment to monitor treatment response in highly active multiple sclerosis patients","volume":"23","author":"N\u00f6tzel","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106550_bib0038","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106550_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.819010","article-title":"Renal function and body mass index contribute to serum neurofilament light chain levels in elderly patients with atrial fibrillation","volume":"16","author":"Polymeris","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.msard.2025.106550_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044067","article-title":"Serum neurofilament light chain as biomarker for cladribine-treated multiple sclerosis patients in a real-world setting","volume":"24","author":"Seiberl","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106550_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1354431","article-title":"Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis","volume":"15","author":"Sol\u00eds-Tarazona","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106550_bib0015","first-page":"1","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci. Reports"},{"key":"10.1016\/j.msard.2025.106550_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103590","article-title":"NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study","volume":"72","author":"Uphaus","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106550_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103090","article-title":"Serum neurofilament light chain levels in healthy individuals: a proposal of cut-off values for use in multiple sclerosis clinical practice","volume":"54","author":"Valentino","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106550_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104893","article-title":"Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients","volume":"77","author":"Valentino","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106550_bib0037","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1515\/cclm-2022-0007","article-title":"Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1","volume":"60","author":"Van Lierop","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.msard.2025.106550_bib0004","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106550_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105412","article-title":"Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA TM, Ella TM, and Lumipulse TM in multiple sclerosis naive patients","volume":"82","author":"Vecchio","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106550_bib0020","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1038\/s41598-021-88624-7","article-title":"Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment","volume":"11","author":"Walo-Delgado","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106550_bib0001","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1515\/cclm-2023-0518","article-title":"Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury","volume":"62","author":"Wilson","year":"2024","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:12:07Z","timestamp":1754003527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":39,"alternative-id":["S2211034825002925"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106550","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106550"}}